search
Back to results

Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy

Primary Purpose

Nephropathy

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
100% oxigen
placebo
Sponsored by
Assaf-Harofeh Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Nephropathy focused on measuring contrast induced nephropathy, oxigen, coronary angiography

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • elective coronary angiography
  • estimated GFR base on the MDRD equation of less than 60 mL/min/1.73 m2
  • inform consent

Exclusion Criteria:

  • acute renal failure
  • acute myocardial infarction
  • noncompensated congestive heart failure
  • hemodynamic instability
  • known sensitivity to contrast media
  • patients who had been exposed to contrast media during the last 3 months
  • Patients with oxygen blood saturation of less than 94% at room air.

Sites / Locations

  • Intensive Cardiac Care Unit, assaf harofhe medical centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

100% oxigen

placebo

Arm Description

patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination

patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination

Outcomes

Primary Outcome Measures

contrast induced nephropathy

Secondary Outcome Measures

Nitric Oxide in urine sample
urinary isoprostanes
blood urea and creatinin
cystatin-C

Full Information

First Posted
April 6, 2011
Last Updated
October 6, 2011
Sponsor
Assaf-Harofeh Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01448889
Brief Title
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy
Official Title
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2011
Overall Recruitment Status
Unknown status
Study Start Date
September 2009 (undefined)
Primary Completion Date
September 2012 (Anticipated)
Study Completion Date
December 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assaf-Harofeh Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute renal failure induced by radiographic contrast agents is a known complication of coronary angiography.hypoxia plays a major role in the pathogenesis of Contrast induced nephropathy. The aim of the current study is to investigate the effect of normobaric hyperoxygenation therapy on renal functions in patients at high risk for CIN undergoing coronary angiography. The study is aimed to include 180 consecutive patients with estimated GFR base on the MDRD equation of less than 60 mL/min/1.73 m2 that are candidates for elective coronary angiography. Patients with acute renal failure, acute myocardial infarction, noncompensated congestive heart failure, hemodynamic instability, known sensitivity to contrast media and patients who had been exposed to contrast media during the last 3 months will be excluded. Patients with oxygen blood saturation of less than 94% at room air will also be excluded from the study. Study protocol Patients will be randomly assigned to receive either 100% oxygen by mask (treated group) or breath room air (control group) for duration of 4 hours starting at the beginning of the angiographic procedure. All patients will be treated with 0.9% salin and NAC. Coronary angiography will be performed using nonionic, low osmolar iodine (Ultravist®-370) (Schering, Berlin, Germany). All patients will be hospitalized 1 day before and at least 24 hours following angiography. Blood samples for urea, creatinine and cystatin- C will be drawn on admission, 6, 24 and 48 hours after coronary angiography. Urine sample will be taken 24 hours before angiography and 6, 24 and 48 hours post angiography. In those urine samples the ratio between creatinine to Isoprostanes and NO will be evaluated.
Detailed Description
Acute renal failure induced by radiographic contrast agents is a known complication of coronary angiography. It has been demonstrated that following contrast media application the renal outer medullar blood flow is reduced, resulting in medullar ischemia. N-acetylcysteine (NAC) together with well hydration stands in the center of treatments to prevent contrast induced nephropaathy (CIN). Since, hypoxia plays a major role in the pathogenesis of CIN it seems rational that further increase oxygen delivery to the renal tissue will further ameliorate the expected CIN. The aim of the current study is to investigate the effect of normobaric hyperoxygenation therapy on renal functions in patients at high risk for CIN undergoing coronary angiography. The study protocol was approved by the local Ethics Committee and each patient will give written informed consent before including in the study. The study is aimed to include 180 consecutive patients with estimated GFR base on the MDRD equation of less than 60 mL/min/1.73 m2 that are candidates for elective coronary angiography. Patients with acute renal failure, acute myocardial infarction, noncompensated congestive heart failure, hemodynamic instability, known sensitivity to contrast media and patients who had been exposed to contrast media during the last 3 months will be excluded. Patients with oxygen blood saturation of less than 94% at room air will also be excluded from the study. Study protocol Patients will be randomly assigned to receive either 100% oxygen by mask (treated group) or breath room air (control group) for duration of 4 hours starting at the beginning of the angiographic procedure. All patients will be treated with 0.9% salin and NAC. Saline o.9% hydration will be infused at a rate of 1 mL/kg/hour 12 hours before and 12 hours after coronary angiography. NAC 1g [Mucomyst 20% solution (Bristol-Meyers, New York, NY, USA)] will be administered orally twice daily 24 hours before and 24 hours after coronary angiography. Coronary angiography will be performed using nonionic, low osmolar iodine (Ultravist®-370) (Schering, Berlin, Germany). All patients will be hospitalized 1 day before and at least 24 hours following angiography. Blood samples for urea, creatinine and cystatin- C will be drawn on admission, 6, 24 and 48 hours after coronary angiography. Urine sample will be taken 24 hours before angiography and 6, 24 and 48 hours post angiography. In those urine samples the ratio between creatinine to Isoprostanes and NO will be evaluated. Laboratory analysis Two 10mL aliquots from each urine collection will be separated and stored at -70°C until analyzed for nitric oxide metabolites and urinary isoprostanes. Measurement of urinary nitric oxide metabolites Metabolites of nitric oxide (NOx) (NO2+ NO3) will be measured in the urine samples. Total NO synthesis will be evaluated in duplicates, by a specific two-step photocolorimetric assay (R&D Systems, USA) by a protocol supplied by a manufacturer. The intensity of the developing color was measured in ELISA reader, at 540 nm wavelength. Oxidative stress Oxidative stress will be assessed by measurement of urinary isoprostanes, which are secondary end products of lipid peroxidation and are known to be an accurate and sensitive marker of renal oxidative stress in vivo. STAT-8 isoprostane PGF2 content will be estimated by a specific EIA (Cayman Chemical Co., Ann Arbor, Mich., USA) based on a competition between 8-isoprostane and 8-isoprostane-alkaline phosphatase conjugate for a limited number of the specific STAT-8 isoprostane PGF2 antibody binding sites and subsequent reaction of the immobilized complex with p-nitrophenyl-phosphate. The intensity of the developing yellow color will be measured in ELISA reader at 405 nm wavelength. Investigators involved in the measurement of blood urea, creatinin and cystatin-C and in the urinary NOx and isoprostanes will be blinded to the patients' treatment. Statistical analysis The calculation of the sample size is based on the following assumption: Baseline frequency of CIN of 20%, at least 35% reduction in the control group, alpha error level of 5%, beta error level of 50% and expected drop out rate of 15%. Continuous baseline variables will be compared between the treatment groups by an unpaired t test and by a paired t test within each group. Categorical parameters will compared by a chi-square test. The effect of oxygen therapy on serum urea, creatinine, serum urea, serum cystatin-C, urinary NOx, and urinary isoprostanes at baseline 6, 24 and 48 hours following angiography will be compared between the groups by a general linear model repeated-measures analysis of variance (ANOVA). The statistical software SPSS (version 13.0, SPSS, Inc., Chicago, IL, USA) will be used for all analyses. All tests were two tailed. P values below 0.05 were considered significant. Data are expressed as mean SEM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nephropathy
Keywords
contrast induced nephropathy, oxigen, coronary angiography

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
100% oxigen
Arm Type
Active Comparator
Arm Description
patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Intervention Type
Drug
Intervention Name(s)
100% oxigen
Intervention Description
patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Primary Outcome Measure Information:
Title
contrast induced nephropathy
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Nitric Oxide in urine sample
Time Frame
day -1, and 6,24,48 hours after exposure
Title
urinary isoprostanes
Time Frame
day -1, and 6,24,48 hours after exposure
Title
blood urea and creatinin
Time Frame
day -1, and 6,24,48 hours after exposure
Title
cystatin-C
Time Frame
day -1, and 6,24,48 hours after exposure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: elective coronary angiography estimated GFR base on the MDRD equation of less than 60 mL/min/1.73 m2 inform consent Exclusion Criteria: acute renal failure acute myocardial infarction noncompensated congestive heart failure hemodynamic instability known sensitivity to contrast media patients who had been exposed to contrast media during the last 3 months Patients with oxygen blood saturation of less than 94% at room air.
Facility Information:
Facility Name
Intensive Cardiac Care Unit, assaf harofhe medical center
City
Zerifin
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sahar Minha, Dr
Email
minha.saar@gmail.com
First Name & Middle Initial & Last Name & Degree
Keren Doenyas, Dr
Phone
972-544-215487
Email
kerendoenyas@gmail.com
First Name & Middle Initial & Last Name & Degree
Alex Blat, Dr

12. IPD Sharing Statement

Learn more about this trial

Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy

We'll reach out to this number within 24 hrs